Allopurinol improves endothelial function and reduces oxidant-inflammatory enzyme of myeloperoxidase in metabolic syndrome

Clinical Research in Cardiology

Volumn 97, Issue 5, 2008, Pages 334-340

  Yiginer, Omer ^a,d   Ozcelik, Fatih ^a   Inanc, Tugrul ^a   Aparci, Mustafa ^b   Ozmen, Namik ^b   Cingozbay, Bekir Yilmaz ^b   Kardesoglu, Ejder ^b   Suleymanoglu, Selami ^b   Sener, Goksel ^c   Cebeci, Bekir Sitki ^b  

^a Gumussuyu Military Hospital   (Turkey)

^b GATA HAYDARPASA TRAINING HOSPITAL   (Turkey)

^c MARMARA UNIVERSITY   (Turkey)

^d Gumussuyu Asker Hastanesi   (Turkey)

Author keywords

Allopurinol; C reactive protein; Endothelial dysfunction; Metabolic syndrome; Myeloperoxidase

Indexed keywords

ALLOPURINOL; BIOLOGICAL MARKER; C REACTIVE PROTEIN; FIBRINOGEN; MYELOPEROXIDASE; PLACEBO;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; BRACHIAL ARTERY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; MALE; METABOLIC SYNDROME X; OUTCOME ASSESSMENT; OXIDATIVE STRESS; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL;

AGED; ALLOPURINOL; BLOOD FLOW VELOCITY; BRACHIAL ARTERY; C-REACTIVE PROTEIN; DOUBLE-BLIND METHOD; ENDOTHELIUM, VASCULAR; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBRINOGEN; FOLLOW-UP STUDIES; FREE RADICAL SCAVENGERS; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OXIDATIVE STRESS; PEROXIDASE; SPECTROPHOTOMETRY; TREATMENT OUTCOME; VASODILATION;

EID: 44349148871     PISSN: 18610684     EISSN: 18610692     Source Type: Journal    
DOI: 10.1007/s00392-007-0636-3     Document Type: Article

References (34)

1. Baldus S, Meinertz T (2006) Current concepts of diabetic atherogenesis. Clin Res Cardiol 95(Suppl 1):i1-i6
2. Boudjeltia KZ, Legssyer I, Van Antwerpen P, Kisoka RL, Babar S, Moguilevsky N, Delree P, Ducobu J, Remacle C, Vanhaeverbeek M, Brohee D (2006) Triggering of inflammatory response by myeloperoxidase-oxidized LDL. Biochem Cell Biol (Biochimie et biologie cellulaire) 84:805-812
3. Brennan ML, Penn MS, Van Lente F, Nambi V, Shishehbor MH, Aviles RJ, Goormastic M, Pepoy ML, McErlean ES, Topol EJ, Nissen SE, Hazen SL (2003) Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Medi 349:1595-1604
4. Butler R, Morris AD, Belch JJ, Hill A, Struthers AD (2000) Allopurinol normalizes endothelial dysfunction in type 2 diabetics with mild hypertension. Hypertension 35:746-751
5. Cardillo C, Kilcoyne CM, Cannon RO 3rd, Quyyumi AA, Panza JA (1997) Xanthine oxidase inhibition with oxypurinol improves endothelial vasodilator function in hypercholesterolemic but not in hypertensive patients. Hypertension 30:57-63
6. Daugherty A, Dunn JL, Rateri DL, Heinecke JW (1994) Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions. J Clin Invest 94:437-444
7. E B (1975) Glutathione in red blood cell metabolism. A manual of biochemical methods. Grune & Stratton, New York, pp 112-114
8. Farquharson CA, Butler R, Hill A, Belch JJ, Struthers AD (2002) Allopurinol improves endothelial dysfunction in chronic heart failure. Circulation 106:221-226
9. Foote CS, Goyne TE, Lehrer RI (1983) Assessment of chlorination by human neutrophils. Nature 301:715-716
10. Friedl HP, Smith DJ, Till GO, Thomson PD, Louis DS, Ward PA (1990) Ischemia-reperfusion in humans. Appearance of xanthine oxidase activity. Am J Pathol 136:491-495
11. Fu X, Kassim SY, Parks WC, Heinecke JW (2001) Hypochlorous acid oxygenates the cysteine switch domain of pro-matrilysin (MMP-7). A mechanism for matrix metalloproteinase activation and atherosclerotic plaque rupture by myeloperoxidase. J Biol Chem 276:41279-41287
12. George J, Carr E, Davies J, Belch JJ, Struthers A (2006) High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid. Circulation 114:2508-2516
13. Girotti MJ, Khan N, McLellan BA (1991) Early measurement of systemic lipid peroxidation products in the plasma of major blunt trauma patients. J Trauma 31:32-35
14. Godsland IF, Crook D, Proudler AJ, Stevenson JC (2005) Hemostatic risk factors and insulin sensitivity, regional body fat distribution, and the metabolic syndrome. J Clin Endocrinol Metab 90:190-197
15. Guthikonda S, Sinkey C, Barenz T, Haynes WG (2003) Xanthine oxidase inhibition reverses endothelial dysfunction in heavy smokers. Circulation 107:416-421
16. Harrison JE, Schultz J (1976) Studies on the chlorinating activity of myeloperoxidase. J Biol Chem 251:1371-1374
17. Ishizaka N, Ishizaka Y, Toda EI, Hashimoto H, Nagai R, Yamakado M (2007) Higher serum uric acid is associated with increased arterial stiffness in Japanese individuals. Atherosclerosis 192:131-137
18. Jarasch ED, Grund C, Bruder G, Heid HW, Keenan TW, Franke WW (1981) Localization of xanthine oxidase in mammary-gland epithelium and capillary endothelium. Cell 25:67-82
19. Kahn SE, Zinman B, Haffner SM, O'Neill MC, Kravitz BG, Yu D, Freed MI, Herman WH, Holman RR, Jones NP, Lachin JM, Viberti GC (2006) Obesity is a major determinant of the association of C-reactive protein levels and the metabolic syndrome in type 2 diabetes. Diabetes 55:2357-2364
20. Leichman JG, Lavis VR, Aguilar D, Wilson CR, Taegtmeyer H (2006) The metabolic syndrome and the heart: a considered opinion. Clin Res Cardiol 95:i134-i141
21. Libby P, Ridker PM, Maseri A (2002) Inflammation and atherosclerosis. Circulation 105:1135-1143
22. Matsuura E, Kobayashi K, Tabuchi M, Lopez LR (2006) Oxidative modification of low-density lipoprotein and immune regulation of atherosclerosis. Prog Lipid Res 45:466-486
23. Milionis HJ, Kalantzi KJ, Goudevenos JA, Seferiadis K, Mikhailidis DP, Elisaf MS (2005) Serum uric acid levels and risk for acute ischaemic non-embolic stroke in elderly subjects. J Intern Medi 258:435-441
24. Roberts CK, Won D, Pruthi S, Kurtovic S, Sindhu RK, Vaziri ND, Barnard RJ (2006) Effect of a short-term diet and exercise intervention on oxidative stress, inflammation, MMP-9, and monocyte chemotactic activity in men with metabolic syndrome factors. J Appl Physiol 100:1657-1665
25. Sugiyama S, Kugiyama K, Aikawa M, Nakamura S, Ogawa H, Libby P (2004) Hypochlorous acid, a macrophage product, induces endothelial apoptosis and tissue factor expression: involvement of myeloperoxidase-mediated oxidant in plaque erosion and thrombogenesis. Arterioscler Thromb Vascr Biol 24:1309-1314
26. Tabuchi M, Inoue K, Usui-Kataoka H, Kobayashi K, Teramoto M, Takasugi K, Shikata K, Yamamura M, Ando K, Nishida K, Kasahara J, Kume N, Lopez LR, Mitsudo K, Nobuyoshi M, Yasuda T, Kita T, Makino H, Matsuura E (2007) The association of C-reactive protein with an oxidative metabolite of LDL and its implication in atherosclerosis. J Lipid Res 48:768-781
27. Tang W, Hong Y, Province MA, Rich SS, Hopkins PN, Arnett DK, Pankow JS, Miller MB, Eckfeldt JH (2006) Familial clustering for features of the metabolic syndrome: the National Heart, Lung, and Blood Institute (NHLBI) Family Heart Study. Diabetes Care 29:631-636
28. Tschoepe D, Roesen P, Scherbaum WA (1999) The heart and metabolic syndrome. Z Kardiol 88:215-224
29. Vita JA (2002) Nitric oxide-dependent vasodilation in human subjects. Meth Enzymol 359:186-200
30. Vita JA, Keaney JF Jr. (2002) Endothelial function: a barometer for cardiovascular risk? Circulation 106:640-642
31. Vita JA, Brennan ML, Gokce N, Mann SA, Goormastic M, Shishehbor MH, Penn MS, Keaney JF Jr., Hazen SL (2004) Serum myeloperoxidase levels independently predict endothelial dysfunction in humans. Circulation 110:1134-1139
32. Yamaguchi Y, Yoshikawa N, Kagota S, Nakamura K, Haginaka J, Kunitomo M (2006) Elevated circulating levels of markers of oxidative-nitrative stress and inflammation in a genetic rat model of metabolic syndrome. Nitric Oxide 15:380-386
33. Yoo TW, Sung KC, Shin HS, Kim BJ, Kim BS, Kang JH, Lee MH, Park JR, Kim H, Rhee EJ, Lee WY, Kim SW, Ryu SH, Keum DG (2005) Relationship between serum uric acid concentration and insulin resistance and metabolic syndrome. Circ J 69:928-933
34. Zhang R, Brennan ML, Fu X, Aviles RJ, Pearce GL, Penn MS, Topol EJ, Sprecher DL, Hazen SL (2001) Association between myeloperoxidase levels and risk of coronary artery disease. JAMA 286:2136-2142